2026年1月30日，美国基因测序巨头因美纳（Illumina）宣布完成对蛋白质组学企业SomaLogic的收购。交易以3.5亿美元现金从Standard BioTools购得SomaLogic及相关资产，并附带最高7500万美元绩效里程碑款及后续业绩版税，资金源自公司自有现金。此次收购旨在整合基因组学与蛋白质组学技术，强化药物研发支持能力。因美纳计划于2月5日财报电话会议中披露交易财务影响。
Source Link2026年1月30日，美国基因测序巨头因美纳（Illumina）宣布完成对蛋白质组学企业SomaLogic的收购。交易以3.5亿美元现金从Standard BioTools购得SomaLogic及相关资产，并附带最高7500万美元绩效里程碑款及后续业绩版税，资金源自公司自有现金。此次收购旨在整合基因组学与蛋白质组学技术，强化药物研发支持能力。因美纳计划于2月5日财报电话会议中披露交易财务影响。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.